Vertex Pharmaceuticals Inc (VRTX)vsXTL Biopharmaceuticals Ltd ADR (XTLB)
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
XTLB
XTL Biopharmaceuticals Ltd ADR
$2.71
+315.01%
HEALTHCARE · Cap: $5.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1239704% more annual revenue ($12.00B vs $968,000). VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
VRTX
Strong Buy66
out of 100
Grade: B-
XTLB
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Intrinsic value data unavailable for XTLB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
0.0% revenue growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bull Case : XTLB
The strongest argument for XTLB centers on Debt/Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : XTLB
The primary concerns for XTLB are Revenue Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
VRTX profiles as a mature stock while XTLB is a value play — different risk/reward profiles.
XTLB carries more volatility with a beta of 0.73 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (66/100 vs 25/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
XTL Biopharmaceuticals Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company is headquartered in Ramat Gan, Israel.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?